Advertisement

Radiation Therapy in Gynecologic Cancer

  • Susan G. R. McDuff
  • Catheryn M. Yashar
Chapter

Abstract

This book chapter presents a broad overview of the biology of radiation therapy and the modalities of radiation delivery including intensity modulated radiation therapy (IMRT), brachytherapy, interstitial therapy, and external beam radiation therapy.

The chapter also discusses the major clinical trials supporting the use of radiation therapy in the treatment of gynecologic malignancies involving the endometrium, cervix, vagina, and vulva, as well as a brief overview of radiation therapy in patients with ovarian, primary peritoneal, and fallopian tube carcinoma. The role for palliative radiation therapy in gynecologic malignancies is discussed at the end of the chapter.

Keywords

Radiation therapy Gynecologic oncology Radiobiology Intensity modulated radiation therapy Brachytherapy Cervical cancer Endometrial cancer Vaginal and vulvar cancer 

References

  1. 1.
    Sarkaria, JN, Bristow RG. “Overview of cancer molecular radiobiology.” In Radiation Oncology Advances, pp. 115–131. Springer US, 2008.Google Scholar
  2. 2.
    Yashar CM. “Basic Principle in Gynecologic Radiotherapy.” Clinical Gynecology Oncology 7ed. Philadelphia: Mosby 94 2007.Google Scholar
  3. 3.
    Disilvestro PA, Ali S, Craighead PS, Lucci JA, Lee Y-C, Cohn DE, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014; 32: no. 5, 458–464.Google Scholar
  4. 4.
    Tewari KS, DiSaia PJ. Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res. 2002;28:123–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:428–34.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Viswanathan AN, Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11:33–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419–27.PubMedGoogle Scholar
  10. 10.
    Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2001;51:1246–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Scholten AN, van Putten WLJ, Beerman H, Smit VTHBM, Koper PCM, Lybeert MLM, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Nout RA, van de Poll-Franse LV, Lybeert MLM, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JWM, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29:1692–700.PubMedCrossRefGoogle Scholar
  14. 14.
    Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Nout RA, Smit VTHBM, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95:266–71.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422–31.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:543–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Einstein MH, Frimer M, Kuo DY-S, Reimers LL, Mehta K, Mutyala S, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol. 2012;124:21–5.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Secord AA, Havrilesky LJ, O’Malley DM, Bae-Jump V, Fleming ND, Broadwater G, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol. 2009;114:442–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001;164:1017–25.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Grigsby PW, Perez CA. Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. Int J Radiat Oncol Biol Phys. 1991;21:375–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol. 1989;33:265–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Keys HM, Bundy BN, Stehman FB, Okagaki T, Gallup DG, Burnett AF, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003;89:343–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Wolfson AH, Varia MA, Moore D, Rao GG, Gaffney DK, Erickson-Wittmann BA, et al. ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer. Gynecol Oncol. 2012;125:256–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Gaffney DK, Erickson-Wittmann BA, Jhingran A, Mayr NA, Puthawala AA, Moore D, et al. ACR Appropriateness Criteria® on advanced cervical cancer expert panel on radiation oncology-gynecology. Int J Radiat Oncol Biol Phys. 2011;81:609–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Stehman FB, Ali S, Keys HM, Muderspach LI, Chafe WE, Gallup DG, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197:503.e1–6.CrossRefGoogle Scholar
  32. 32.
    Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–48.PubMedGoogle Scholar
  33. 33.
    Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.PubMedCrossRefGoogle Scholar
  34. 34.
    Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs 3rd CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.PubMedCrossRefGoogle Scholar
  36. 36.
    Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMedGoogle Scholar
  37. 37.
    Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Ito K, Tsutui T, et al. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes. Int J Gynecol Cancer. 2013;23:1279–86.PubMedCrossRefGoogle Scholar
  39. 39.
    Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177–83.PubMedCrossRefGoogle Scholar
  40. 40.
    Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol. 2008;108:577–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990;38:309–14.PubMedCrossRefGoogle Scholar
  42. 42.
    Faul CM, Mirmow D, Huang Q, Gerszten K, Day R, Jones MW. Adjuvant radiation for vulvar carcinoma: improved local control. Int J Radiat Oncol Biol Phys. 1997;38:381–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Kidd E, Moore D, Varia MA, Gaffney DK, Elshaikh MA, Erickson B, et al. ACR Appropriateness Criteria® management of locoregionally advanced squamous cell carcinoma of the vulva. Am J Clin Oncol. 2013;36:415–22.PubMedCrossRefGoogle Scholar
  44. 44.
    Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:79–85.PubMedCrossRefGoogle Scholar
  45. 45.
    Moore DH, Ali S, Koh W-J, Michael H, Barnes MN, McCourt CK, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012;124:529–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Wu X, Matanoski G, Chen VW, Saraiya M, Coughlin SS, King JB, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008;113:2873–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998;83:1033–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 2005;62:138–47.PubMedCrossRefGoogle Scholar
  49. 49.
    Sinha B, Stehman F, Schilder J, Clark L, Cardenes H. Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer. 2009;19:686–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Hegemann S, Schäfer U, Lellé R, Willich N, Micke O. Long-term results of radiotherapy in primary carcinoma of the vagina. Strahlenther Onkol. 2009;185:184–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Mock U, Kucera H, Fellner C, Knocke TH, Pötter R. High-dose-rate (HDR) brachytherapy with or without external beam radiotherapy in the treatment of primary vaginal carcinoma: long-term results and side effects. Int J Radiat Oncol Biol Phys. 2003;56:950–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Stock RG, Mychalczak B, Armstrong JG, Curtin JP, Harrison LB. The importance of brachytherapy technique in the management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 1992;24:747–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Perez CA, Grigsby PW, Garipagaoglu M, Mutch DG, Lockett MA. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys. 1999;44:37–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Kucera H, Mock U, Knocke TH, Kucera E, Pötter R. Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. Acta Obstet Gynecol Scand. 2001;80:355–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Nashiro T, Yagi C, Hirakawa M, Inamine M, Nagai Y, Sakumoto K, et al. Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. Int J Clin Oncol. 2008;13:335–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Samant R, Lau B, E C, Le T, Tam E. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys. 2007;69:746–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer. 2004;14:110–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Kirkbride P, Fyles A, Rawlings GA, Manchul L, Levin W, Murphy KJ, et al. Carcinoma of the vagina–experience at the Princess Margaret Hospital (1974–1989). Gynecol Oncol. 1995;56:435–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Eltabbakh GH, Piver MS. Extraovarian primary peritoneal carcinoma. Oncology (Williston Park). 1998;12:813–9. discussion 820, 825–6.Google Scholar
  60. 60.
    Bhuyan P, Mahapatra S, Mahapatra S, Sethy S, Parida P, Satpathy S. Extraovarian primary peritoneal papillary serous carcinoma. Arch Gynecol Obstet. 2010;281:561–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169:155–61.PubMedCrossRefGoogle Scholar
  62. 62.
    Klein M, Rosen A, Lahousen M, Graf A-H, Rainer A. The relevance of adjuvant therapy in primary carcinoma of the fallopian tube, stages I and II: irradiation vs. chemotherapy. Int J Radiat Oncol. 2000;48:1427–31.CrossRefGoogle Scholar
  63. 63.
    Spanos WJ, Wasserman T, Meoz R, Sala J, Kong J, Stetz J. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study. Int J Radiat Oncol Biol Phys. 1987;13:1479–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Spanos WJ, Clery M, Perez CA, Grigsby PW, Doggett RL, Poulter CA, et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys. 1994;29:961–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Radiation Medicine and Applied SciencesUniversity of California San Diego Health SystemLa JollaUSA

Personalised recommendations